TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28690041

Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 g IV)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen (1 g oral)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (oral placebo and volume-matched IV normal saline)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 25493970

Group type: EXPERIMENTAL
Intervention: High exposure antibiotic therapy (n = 604)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard exposure antibiotic therapy (n = 596)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (used for 3 days)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (used for 1-2 days)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-containing regimens (first 3 days)
Number of subjects: 1200
Study: 25083776

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Artificial tears (AT)
Number of subjects: 118
Study: 21484454

Group type: EXPERIMENTAL
Intervention: Photogem® gel 50 mg/l (P50G)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photogem® gel 100 mg/l (P100G)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photogem® suspension 50 mg/l (P50S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photogem® suspension 100 mg/l (P100S)
Number of subjects: 60
Study: 20002742

Group type: EXPERIMENTAL
Intervention: Xeomin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 300
Study: 17892376

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily for 5 years
Number of subjects: 10101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study: 15939222

Group type: EXPERIMENTAL
Intervention: Clear diagnosis and reassurance that they would soon be better
Number of subjects: 128

Group type: COMPARATOR
Intervention: Negative consultation with no clear diagnosis, advised to return if necessary
Number of subjects: 128
Study: 12007554

Group type: EXPERIMENTAL
Intervention: Interviewer-administered questionnaire
Number of subjects: 234

Group type: COMPARATOR
Intervention: Self-administered questionnaire
Number of subjects: 234
Study: 10570754

Group type: EXPERIMENTAL
Intervention: Left prefrontal transcranial magnetic stimulation (TMS) for 2 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 22
Study: 8759893

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone + interferon alpha-2b (5 million units subcutaneously, 3 d/week)
Number of subjects: 583

Group type: COMPARATOR
Intervention: melphalan-prednisone
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone + interferon alpha-2b
Number of subjects: 583
Study: 1929687

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 315
Study: 6414505

Group type: EXPERIMENTAL
Intervention: 30 micrograms + 150 micrograms ethinyl oestradiol and levonorgestrel
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 50 micrograms + 250 micrograms ethinyl oestradiol and levonorgestrel
Number of subjects: 142

Group type: COMPARATOR
Intervention: Reference group using other contraceptive methods
Number of subjects: 142
Study: 30312182

Group type: EXPERIMENTAL
Intervention: Alert group (received alerts for triple-low events)
Number of subjects: 7569

Group type: COMPARATOR
Intervention: Nonalert group (did not receive alerts for triple-low events)
Number of subjects: 7569

Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 7569

Group type: COMPARATOR
Intervention: Nonalert group
Number of subjects: 7569
Study: 27852953

Group type: EXPERIMENTAL
Intervention: 6-week exercise programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 25336165

Group type: EXPERIMENTAL
Intervention: Oral cefalexin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Parenteral cefazolin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral cefalexin and Parenteral cefazolin
Number of subjects: 47
Study: 24333069

Group type: EXPERIMENTAL
Intervention: Cross-match-compatible platelets
Number of subjects: 31

Group type: COMPARATOR
Intervention: Incompatible single donor platelet transfusions
Number of subjects: 31
Study: 23193340

Group type: EXPERIMENTAL
Intervention: Simulation-based IPPE
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (hospital and specialty IPPEs)
Number of subjects: 28
Study: 19615131

Group type: EXPERIMENTAL
Intervention: Xuebijing injection (100 ml twice a day for 7 days)
Number of subjects: 61
Study: 17524720

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (nitrogen and >or=10 kcal/kg/day of non‐protein calories for >or=5 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Protein-sparing therapy (nitrogen and fewer non‐protein calories)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 100

Group type: COMPARATOR
Intervention: No artificial nutrition (beyond regular food and/or standard (5%) dextrose)
Number of subjects: 100
Study: 15177700

Group type: EXPERIMENTAL
Intervention: Hexarelin (4 x 50 microg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11397745

Group type: COMPARATOR
Intervention: Non-tailored letter
Number of subjects: 2553

Group type: COMPARATOR
Intervention: Tailored letter
Number of subjects: 2553

Group type: COMPARATOR
Intervention: No letter
Number of subjects: 2553
Study: 9521635

Group type: EXPERIMENTAL
Intervention: Isoflavonoids (55 mg daily, predominantly genistein)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 59
Study: 8113849

Group type: EXPERIMENTAL
Intervention: FAMe (5‐FU, doxorubicin, and methyl lomustine)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: FAP (5‐FU, doxorubicin, and cisplatin)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: FAMe alternating with TZT (triazinate)
Number of subjects: 252

Group type: COMPARATOR
Intervention: 5‐FU alone (control)
Number of subjects: 252
Study: 2837545

Group type: EXPERIMENTAL
Intervention: Microtraining in six basic communication skills (approximately 25 hours)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Microtraining in six basic communication skills
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nonattention control group
Number of subjects: 53
Study: 30110103

Group type: EXPERIMENTAL
Intervention: Therapeutic listening
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no therapeutic listening)
Number of subjects: 50
Study: 28445783

Group type: EXPERIMENTAL
Intervention: SMA group that combines low‐carbohydrate diet‐focused weight management (WM/SMA) with medication management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional SMA group focusing on medication management and self‐management counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WM/SMA
Number of subjects: 0
Study: 25619124

Group type: EXPERIMENTAL
Intervention: Centchroman 30mg daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen 10mg daily for 12 weeks
Number of subjects: 0
Study: 23933145

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg) given as nicotine gum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 21035560

Group type: EXPERIMENTAL
Intervention: Salmeterol 25 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 μg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 18302293

Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic lamivudine treatment
Number of subjects: 0
Study: 17354817

Group type: EXPERIMENTAL
Intervention: Statistical analysis of vessel shape using MRA
Number of subjects: 16
Study: 12697482

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCBPA) with a mixture of 1% lidocaine and 0.25% bupivacaine, basal infusion of 2 ml/h, bolus dose of 3 ml, lockout time of 45 min.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group without postoperative analgesia.
Number of subjects: 24
Study: 10321416

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg once daily for 4 weeks, followed by 16 mg once daily for 4 weeks
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg twice daily for 4 weeks
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (once and twice daily)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (once daily)
Number of subjects: 277
Study: 8793457

Group type: EXPERIMENTAL
Intervention: nCPAP (6 cmH2O for ten minutes) in RUAO group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: nCPAP in asthmatics
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: nCPAP in COPD patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: nCPAP in RUAO and asthmatics
Number of subjects: 37
Study: 1895355

Group type: EXPERIMENTAL
Intervention: Cadence and power output variations (60, 80, 100 rev min‐1; 100 and 235 W)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cadence increase
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison between competitive and recreational cyclists
Number of subjects: 45
Study: 7050717

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy with dacarbazine
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Surgery plus immunotherapy with bacille Calmette‐Guérin vaccine
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy combined with immunotherapy
Number of subjects: 761

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 761
Study: 30018129

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) chemotherapy
Number of subjects: 0
Study: 28193605

Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment (goal of <120 mm Hg)
Number of subjects: 107500
Study: 26178726

Group type: EXPERIMENTAL
Intervention: C8-dietary oil (13.15 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olive oil (19 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tributyrin (6.53 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carrots (200 g)
Number of subjects: 12
Study: 24152537

Group type: EXPERIMENTAL
Intervention: Simplified Airway Risk Index (SARI)
Number of subjects: 70000

Group type: COMPARATOR
Intervention: Usual non-specific clinical airway assessment
Number of subjects: 70000
Study: 21944891

Group type: EXPERIMENTAL
Intervention: 2mg terbutaline nebulised from an Aeroneb Pro (AERO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5mg terbutaline nebulised from a Sidestream (SIDE)
Number of subjects: 12
Study: 19138954

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16307824

Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated triple-lumen catheter (N=64)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard triple-lumen catheter (N=69)
Number of subjects: 133
Study: 14694225

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary advice and increased physical activity)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (brief leaflet about healthy diet and increased physical activity)
Number of subjects: 88
Study: 10875019

Group type: COMPARATOR
Intervention: Image Tracking System (ImagTrac, Olympus, Tokio)
Number of subjects: 0
Study: 9175299

Group type: EXPERIMENTAL
Intervention: ARTZ (sodium hyaluronate)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8467341

Group type: EXPERIMENTAL
Intervention: Mobilization technique to the involved hip
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manipulative technique for sacroiliac joint dysfunction
Number of subjects: 20
Study: 3007162

Group type: EXPERIMENTAL
Intervention: enalapril 5-10-20 mg bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: propranolol 40-80-120 mg bid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 40
Study: 31411273

Group type: EXPERIMENTAL
Intervention: Hospital birth satisfaction scale (10 items)
Number of subjects: 16109

Group type: EXPERIMENTAL
Intervention: Mother's education level
Number of subjects: 16109

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 16109

Group type: EXPERIMENTAL
Intervention: Having a companion during hospitalization for labor
Number of subjects: 16109
Study: 29271813

Group type: EXPERIMENTAL
Intervention: Individualized endurance + resistance exercises (ICE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional cardiac maintenance program (CMP)
Number of subjects: 70
Study: 26690262

Group type: EXPERIMENTAL
Intervention: Repeat-sprint training in hypoxia (RSH)
Number of subjects: 10
Study: 24646528

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (antibiotics)
Number of subjects: 159
Study: 23462665

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20669669

Group type: EXPERIMENTAL
Intervention: Liandou Qingmai Recipe (LQR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Regular CHD treatment (Control)
Number of subjects: 68
Study: 17962631

Group type: EXPERIMENTAL
Intervention: EUS‐FNA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical staging
Number of subjects: 40
Study: 17491169

Group type: EXPERIMENTAL
Intervention: Thematic promotional releases to print and broadcast media
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Google ads
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Placement of a link on other websites
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Direct mailings to ST users
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Targeted mailings to health care and tobacco control professionals
Number of subjects: 2523

Group type: EXPERIMENTAL
Intervention: Paid advertising
Number of subjects: 2523
Study: 12846768

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 10695392

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg/day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional dose prednisolone (1.0 mg/kg/day)
Number of subjects: 59
Study: 8997580

Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lateral incision
Number of subjects: 168
Study: 1596572

Group type: EXPERIMENTAL
Intervention: Trisomy of chromosomes 4 and 10, n = 180
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Neither or only one of trisomy 4 or 10, n = 73
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Trisomy of chromosomes 4 and 10, n = 19
Number of subjects: 1021
Study: 4028963

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (E) 0.3 mg sub-Q q20min (max 0.9 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nebulized metaproterenol (M) 15 mg in 3.0 ml NaCl 0.9% nebulized over 10 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nebulized metaproterenol (M)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine (E)
Number of subjects: 40
Study: 30887687

Group type: EXPERIMENTAL
Intervention: Steamed, dehydrated, and encapsulated placenta (n = 12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 27
Study: 30535090

Group type: EXPERIMENTAL
Intervention: Sucralose consumption (15% of Acceptable Daily Intake every day for 14 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (same procedures without any intervention)
Number of subjects: 66
Study: 27143183

Group type: EXPERIMENTAL
Intervention: LIRA + hUC-MSCs
Number of subjects: 12

Group type: COMPARATOR
Intervention: LIRA
Number of subjects: 12
Study: 24684263

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI > 95th percentile)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal weight patients (BMI < 85th percentile)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 85th‐95th percentile)
Number of subjects: 48
Study: 20870743

Group type: EXPERIMENTAL
Intervention: Whiteboards in patient rooms on medicine wards
Number of subjects: 0

Group type: COMPARATOR
Intervention: No whiteboards in surgical wards
Number of subjects: 0
Study: 16119515

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg tablets (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Klaricid (reference formulation)
Number of subjects: 24
Study: 11864800

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic regimens (specific regimens not detailed)
Number of subjects: 599
Study: 9661689

Group type: EXPERIMENTAL
Intervention: IO setting of 35
Number of subjects: 17

Group type: COMPARATOR
Intervention: IO setting of 15
Number of subjects: 17
Study: 8055292

Group type: EXPERIMENTAL
Intervention: Unilateral electroconvulsive therapy (U‐ECT) with nondominant long-distance parietotemporal electrode placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral bitemporal electroconvulsive therapy (ECT)
Number of subjects: 0
Study: 3341801

Group type: EXPERIMENTAL
Intervention: Potent topically administered steroids
Number of subjects: 23
Study: 4177135

Group type: EXPERIMENTAL
Intervention: Rh-immune globulin administered at delivery
Number of subjects: 29
Study: 11244765

Group type: EXPERIMENTAL
Intervention: roxatidine acetate hydrochloride 150 mg
Number of subjects: 93
Study: 31453943

Group type: EXPERIMENTAL
Intervention: Integrative neuromuscular training (INT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 32
Study: 30713721

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every 2 weeks
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 29980989

Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block (TAP-lap)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Port-site infiltration (PSI)
Number of subjects: 140
Study: 26953754

Group type: EXPERIMENTAL
Intervention: Briefed scenarios with a structured 4-minute physician-led briefing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Briefed scenarios
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonbriefed scenarios
Number of subjects: 38
Study: 24457144

Group type: EXPERIMENTAL
Intervention: rFVIIa (40μg/kg/hour)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 64
Study: 22768630

Group type: EXPERIMENTAL
Intervention: Spiritually focused group intervention (11 sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 43
Study: 20541828

Group type: EXPERIMENTAL
Intervention: Satavaptan 5mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Satavaptan 25mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 18022577

Group type: EXPERIMENTAL
Intervention: T cell depletion intervention
Number of subjects: 281

Group type: COMPARATOR
Intervention: Existing criteria for primary and contributing CODs
Number of subjects: 281
Study: 15965356

Group type: EXPERIMENTAL
Intervention: Nicorandil (15 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) (40 mg/d)
Number of subjects: 42
Study: 12468478

Group type: EXPERIMENTAL
Intervention: Assessment by appropriately trained nurses
Number of subjects: 1907

Group type: COMPARATOR
Intervention: Assessment by preregistration house officers
Number of subjects: 1907
Study: 9656889

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7806608

Group type: EXPERIMENTAL
Intervention: Hyperactive children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control children
Number of subjects: 0
Study: 2631561

Group type: EXPERIMENTAL
Intervention: Semont's manoeuvre
Number of subjects: 32

Group type: COMPARATOR
Intervention: Classic habituation exercises
Number of subjects: 32
Study: 786429

Group type: EXPERIMENTAL
Intervention: Tyrosine-absorbed Dermatophagoides pteronyssinus vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31765228

Group type: EXPERIMENTAL
Intervention: 8-week weightbearing protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: 12-week weightbearing protocol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combined MRI composite score
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tegner activity score
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tissue structure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Graft failure on MRI
Number of subjects: 70
Study: 31115153

Group type: EXPERIMENTAL
Intervention: Preemptive OLV
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional OLV
Number of subjects: 67
Study: 28732757

Group type: EXPERIMENTAL
Intervention: Supervised multimodal exercise training (progressive aerobic, resistance, and balance) for 6 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Stretching-and-toning activities (control condition) for 6 months
Number of subjects: 83
Study: 26477869

Group type: EXPERIMENTAL
Intervention: Referral to a developmental pediatrician
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: General biochemical testing
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Karyotype genetic testing
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Referral without testing
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Testing only
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Both test and refer
Number of subjects: 1200